Safety and Efficacy of the BTL-043 Device in Alleviating Back Pain
Evaluating the Safety and Efficacy of the BTL-043 Device in Alleviating Back Pain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- Royal Spine Surgery, Scottsdale, AZ, USA
-
-
Colorado
-
Denver, Colorado, United States, 80211
- Aria Integrative Health
-
-
Texas
-
Houston, Texas, United States, 77027
- River Oaks Hospital & Clinics
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult subjects seeking treatment for alleviating back pain, and expressing interest in treatment will be considered eligible for the study.
- Enrollment of the subject will depend on meeting the following criteria:
- Adults seeking alleviation of pain in the treatment area
- Age 22 years and older
- Voluntarily signed an informed consent form
- Subject is willing to comply with study instructions, to return to the clinic for the required visits
- Willingness to adhere to and continue current pain management plan
- Subjects willing and able to maintain their regular (pre-procedure) diet, exercise, and therapy regimen without affecting significant change during study participation
- Subject willing and able to abstain from partaking in any new treatments other than this study procedure to treat back pain
Women of child-bearing potential* are required to use birth control measures during the whole duration of the study
- Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.
Exclusion Criteria:
- A potential subject who meets any of the following criteria will be excluded from participation in the study:
- Major systemic diseases - e.g. uncontrolled Diabetes mellitus, systemic lupus erythematosus
- Ongoing pregnancy
- Photosensitivity, medications affecting sensitivity to light
- Tattoos or other highly-pigmented regions in the treated area
- Corticosteroids or injections of the treated area within the last 3 months, long-term corticosteroids use
- Anticoagulant therapy, bleeding disorders
- Hemorrhage in the treated area
- Application within 4 to 6 months after radiotherapy
- Known or suspected malignancy, history of cancer or any type of malignancy
- Febrile conditions, serious illness, chronic infection
- Epilepsy
- Sensory loss in the treatment area
- Deep vein thrombosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active treatment with 043_CTUS100
|
All patients received four treatment sessions with BTL-043, with treatment sessions spaced 2 to 10 days apart.
The treatment was applied to the upper, middle, or lower back region based on pain location.
BTL-043 uses the TriHIL technology, which combines 1064 nm near-infrared laser energy at a maximum power of 30 W delivered through a hands-free applicator.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in the Oswestry Disability Index (ODI) Score at 3 Months
Time Frame: Baseline and 3 months
|
Oswestry Disability Index (ODI) The ODI will be used to evaluate the presence and impact of pain on the subjects' lives.
The Oswestry Disability Index is a validated questionnaire used in assessment of back related pain and its impact on daily life.
It consists of ten (10) items in total.
The final score (sum of all items) is then calculated as a percentage of maximum possible points (50).
The higher the percentage, the greater the disability.
|
Baseline and 3 months
|
|
Change from Baseline in the Visual Analogue Scale (VAS) Pain Score at 3 Months
Time Frame: Baseline and 3 months
|
The Visual Analogue Scale (VAS) is a self-reported measure used to assess the intensity of back pain experienced by the participants in the treatment area.
Participants rate their perceived pain level on a numerical scale ranging from 0 to 10.
On this scale, 0 is equivalent to "no pain" and 10 indicates the "worst possible pain".
The baseline score is compared to the score collected at the 3-month follow-up visit.
A negative change from baseline (a decrease in the VAS score) indicates a reduction in pain intensity and an improvement in the participant's condition over time.
|
Baseline and 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BTL-043_CTUS100
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.